Sayaka Ishizawa

Sayaka Ishizawa

Auto-generated profile, based on publicly available information

Sayaka Ishizawa

Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2024 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
SISayaka Ishizawa
Sayaka Ishizawa
JNJiangong Niu
Jiangong Niu
MTMartin C Tammemagi
Martin C Tammemagi
EIEhsan Irajizad
Ehsan Irajizad
YSYu Shen
Yu Shen
ITIakovos Toumazis
Iakovos Toumazis
Ovarian cancer is among the leading causes of gynecologic cancer-related death. Past ovarian cancer screening trials using combination of cancer antigen 125 testing and transvaginal ultrasound failed to yield statistically significant mortality reduction. Estimates of ovarian cancer sojourn time—that is, the period from when the cancer is first screen detectable until clinical detection—may inform future screening programs. We modeled ovarian cancer progression as a continuous time Markov chain and estimated screening modality–specific sojourn time and sensitivity using a Bayesian approach. Model inputs were derived from the screening arms (multimodal and ultrasound) of the UK Collaborative Trial of Ovarian Cancer Screening and the Prostate, Lung, Colorectal and Ovarian cancer screening trials. We assessed the quality of our estimates by using the posterior predictive P value. We derived histology-specific sojourn times by adjusting the overall sojourn time based on the corresponding histology-specific survival from the Surveillance, Epidemiology, and End Results Program. The overall ovarian cancer sojourn time was 2.1 years (posterior predictive P value = .469) in the Prostate, Lung, Colorectal and Ovarian studies, with 65.7% screening sensitivity. The sojourn time was 2.0 years (posterior predictive P value = .532) in the United Kingdom Collaborative Trial of Ovarian Cancer Screening’s multimodal screening arm and 2.4 years (posterior predictive P value = .640) in the ultrasound screening arm, with sensitivities of 93.2% and 64.5%, respectively. Stage-specific screening sensitivities in the Prostate, Lung, Colorectal and Ovarian studies were 39.1% and 82.9% for early-stage and advanced-stage disease, respectively. The histology-specific sojourn times ranged from 0.8 to 1.8 years for type II ovarian cancer and 2.9 to 6.6 years for type I ovarian cancer. Annual screening is not effective for all ovarian cancer subtypes. Screening sensitivity for early-stage ovarian cancers is not sufficient for substantial mortality reduction.

1 February 2022 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
MCMinsig Choi
Minsig Choi
SISayaka Ishizawa
Sayaka Ishizawa
DKDavid Kraemer
David Kraemer
ASAaron Sasson
Aaron Sasson
EFEugene Feinberg
Eugene Feinberg

28 July 2024 in eClinicalMedicine
Verified
Journal Article
Open access
MHMehdi Hemmati
Mehdi Hemmati
SISayaka Ishizawa
Sayaka Ishizawa
RMRafael Meza
Rafael Meza
EOEdwin Ostrin
Edwin Ostrin
SHSamir M. Hanash
Samir M. Hanash
ITIakovos Toumazis
Iakovos Toumazis
Lung cancer screening recommendations employ annual frequency for eligible individuals, despite evidence that it may not be universally optimal. The impact of imposing a structure on the screening frequency remains unknown. The ENGAGE framework, a validated framework that offers fully dynamic, analytically optimal, personalised lung cancer screening recommendations, could be used to assess the impact of screening structure on the effectiveness and efficiency of lung cancer screening. In this comparative microsimulation study, we benchmarked alternative clinically relevant structured lung cancer screening programmes employing a fixed (annual or biennial) or adaptive (start with annual/biennial screening and then switch to biennial/annual at ages 60- or 65-years) screening frequency, against the ENGAGE framework. Individuals were eligible for screening according to the 2021 US Preventive Services Task Force recommendation on lung cancer screening. We assessed programmes' efficiency based on the number of screenings per death avoided (LDCT/DA) and the number of screenings per ever-screened individual (LDCT/ESI), and programmes' effectiveness using quality-adjusted life years (QALY) gained from screening, lung cancer-specific mortality reduction (MR), and number of screen-detected lung cancer cases. We used validated natural history, smoking history generator, and risk prediction models to inform our analysis. Sensitivity analysis of key inputs was conducted. ENGAGE was the best performing strategy. Among the structured policies, adaptive biennial-to-annual at age 65 was the best strategy requiring 24% less LDCT/DA and 60% less LDCT/ESI compared to TF2021, but yielded 105 more deaths per 100,000 screen-eligible individuals (10.2% vs. 11.8% MR for TF2021, p = 0.28). Fixed annual screening was the most effective strategy but the least efficient and was ranked as the fifth best strategy. All strategies yielded similar QALYs gained. Adherence levels did not affect the rankings. Adaptive lung cancer screening strategies that start with biennial and switch to annual screening at a prespecified age perform well and warrant further consideration, especially in settings with limited availability of CT scanners and radiologists. National Cancer Institute.

5 July 2025 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
SISayaka Ishizawa
Sayaka Ishizawa
MEMaryam Eghbalizarch
Maryam Eghbalizarch
RNRenu S. Nargund
Renu S. Nargund
SSSeyyed Mostafa Mousavi Janbeh Sarayi
Seyyed Mostafa Mousavi Janbeh Sarayi
JNJiangong Niu
Jiangong Niu
ITIakovos Toumazis
Iakovos Toumazis

28 March 2025 in Lung Cancer
Verified
Journal Article
Open access
RNRenu Sara Nargund
Renu Sara Nargund
SISayaka Ishizawa
Sayaka Ishizawa
MEMaryam Eghbalizarch
Maryam Eghbalizarch
PYPaul Yeh
Paul Yeh
SSSeyyed Mostafa Mousavi Janbeh Saray
Seyyed Mostafa Mousavi Janbeh Saray
ITIakovos Toumazis
Iakovos Toumazis
Natural history models (NHMs) of lung cancer (LC) simulate the disease's natural progression providing a baseline for assessing the impact of interventions. NHMs have been increasingly used to inform public health policies, highlighting their utility. The objective of this scoping review was to summarize existing LC NHMs, identify their limitations, and propose a framework for future NHM development. We searched MEDLINE, Embase, Web of Science, and IEEE Xplore from their inception to October 5, 2023, for peer-reviewed, full-length articles with an LC NHM. Model characteristics, their applications, data sources used, and limitations were extracted and narratively synthesized. From 238 publications, 69 publications were included in our review, corresponding to 22 original LC NHMs and 47 model applications. The majority of the models (n = 15, 68 %) used a microsimulation approach. NHM parameters were predominately informed by cancer registries, trial and institutional data, and literature. Model quality and performance were evaluated in 8 (36 %) models. Twenty (91 %) models included at least one carcinogenesis risk factor-primarily age, sex, and smoking history. Three (14 %) LC NHMs modeled progression in never-smokers; one (5 %) addressed recurrence. Non-tobacco smoking, nodule type, and biomarker expression were not considered in existing NHMs. Based on our findings, we proposed a framework for future LC NHM development which incorporates recurrence, nodule type differentiation, biomarker expression levels, biological factors, and non-smoking-related risk factors. Regular updating and future research are warranted to address limitations in existing NHMs thereby ensuring relevance and accuracy of modeling approaches in the evolving LC landscape.